Background: Cardiovascular diseases (CVD) are the leading cause of mortality and disability globally. An ongoing reform of the Irish healthcare system is underway with a focus on preventing avoidable CVD and lessening its burden to society. However, the high rates of healthcare service use attributable to CVD and the associated costs have not been adequately quantified in Ireland. We examined the difference in health service utilization and costs for populations with and without CVD in Ireland for the period preceding the reform. Methods: Secondary data analysis of the first wave (2009-2011) of The Irish Longitudinal Study on Ageing (TILDA), a nationally representative study of community-dwelling adults in Ireland aged 50+. CVD was defined as having a self-reported doctor's diagnosis of myocardial infarction, angina, heart failure, stroke, atrial fibrillation or transient ischaemic attack. Participants self-reported the utilization of healthcare services over the 12 months preceding the interview. Negative binomial regression with average marginal effects (AME) was used to model the effect of CVD on healthcare service utilization. We estimated the incremental number of general practitioner (GP) and outpatient department (OPD) visits, accident and emergency department (A&E) attendances and hospitalisations in population with CVD relative to population without CVD and calculated the associated costs. Analyses were adjusted for socio-demographic confounders and other chronic conditions. Using census 2022 data on the total number of people aged 50+ living in Ireland, we estimated the total incremental costs attributable to CVD at the population level. Results: Among 8113 participants, the prevalence of CVD was 18.2% (95% confidence interval (CI): 17.3, 19.0). Participants with CVD reported higher utilization of all healthcare services. In adjusted models, having CVD was associated with incremental 1.19 (95% CI: 0.99, 1.39) GP and 0.79 (95% CI: 0.65, 0.93) OPD visits over the past year. There were twice as many incremental hospitalisations in males with CVD compared to females with CVD (AME: 0.20 (95% CI: 0.16, 0.23) for males vs AME: 0.10 (95% CI: 0.07, 0.14) for females), but no difference was observed with respect to the incremental use of other healthcare services by gender or age groups. The incremental cost of healthcare service use in this population relative to the population without CVD were an estimated 352.2 million euro (95% CI: 272.8, 431.7), 93% of which was due to use of secondary care services. Conclusion: There are substantial use of healthcare services and costs associated with CVD in Ireland, with hospital admissions being the biggest contributor to costs. While a shift towards the management of uncomplicated CVD cases in primary care is currently being implemented in Ireland, continued efforts aimed at CVD primary prevention and management are required to contain healthcare service costs. Further research on gender-disparities in the use of healthcare services attributable to CVD is warranted.

The authors have declared no competing interest.

This work was supported by a research grant from the Irish Health Research Board (reference: SDAP-2019-030). The funders had no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript.

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The study used only openly available data that ware originally located at: https://www.ucd.ie/issda/data/tilda/

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors.